TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Brief Summary: Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.


Options:
A: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives
D: Arm Label: Group Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Group Cognitive Behavioral Therapy, Drug: Transdermal Nicotine Patch | Arm Label: General Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Health Education, Drug: Transdermal Nicotine Patch | Intervention Type: BEHAVIORAL; Name: Group Cognitive Behavioral Therapy; Assigned to Arm(s): Group Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: General Health Education; Assigned to Arm(s): General Health Education | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): General Health Education, Group Cognitive Behavioral Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Brief Summary: Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.


Options:
A: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Brief Summary: Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: nicotine lozenge | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch + nicotine lozenge | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bupropion | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: bupropion + lozenge | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: nicotine patch + nicotine lozenge; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Selegiline Transdermal Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selegiline Transdermal Patch, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Selegiline Transdermal Patch; Assigned to Arm(s): Selegiline Transdermal Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Selegiline Transdermal Patch
D: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Brief Summary: Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.


Options:
A: Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Nicotine gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Bupropion+Nicotine Gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Double placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion, Bupropion+Nicotine Gum, Double placebo, Nicotine gum
B: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
C: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Placebo-controlled, Randomised Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil.
Brief Summary: The purpose of this phase IIB MedImmune-sponsored study was to evaluate the efficacy of the HPV-16/18 VLP vaccine in the prevention of infection with HPV-16 and/or HPV-18 in adolescent and young adult women. A vaccine that prevents, or even reduces, the incidence of the common types of high-risk HPVs, particularly HPV-16 and HPV-18, could result in significant reduction in the incidence of cervical cancer and cancer-related mortality, as well as a reduction in the incidence of surgical procedures following abnormal Pap smears.


Options:
A: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V504, Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Biological: Comparator: Placebo (unspecified) | Intervention Type: BIOLOGICAL; Name: V504; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo (unspecified); Assigned to Arm(s): 2
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Aluminium Hydroxide Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Aluminium Hydroxide Group
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.
Brief Summary: The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.


Options:
A: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A
B: Arm Label: Lenalidomide / Dexamethasone until disease progression; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide and low-dose dexamethasone | Arm Label: Lenalidomide / Dexamethasone for 18 cycles; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles | Arm Label: Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan, Prednisone and Thalidomide | Intervention Type: DRUG; Name: Lenalidomide and low-dose dexamethasone; Assigned to Arm(s): Lenalidomide / Dexamethasone until disease progression | Intervention Type: DRUG; Name: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles; Assigned to Arm(s): Lenalidomide / Dexamethasone for 18 cycles | Intervention Type: DRUG; Name: Melphalan, Prednisone and Thalidomide; Assigned to Arm(s): Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles
C: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan/Prednisone/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Prednisone/Velcade | Intervention Type: DRUG; Name: Melphalan/Prednisone/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Prednisone/Velcade; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: San Diego Bleeding Esophageal Varices Study
Brief Summary: In unselected cirrhotic patients with bleeding esophageal varices to compare the influence on mortality rate, duration of life, quality of life, and economic costs of treatment of:

* Emergency portacaval shunt, and
* Emergency and long-term endoscopic sclerotherapy.


Options:
A: Arm Label: Self-expandable esophageal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent | Arm Label: Sengstaken-Blakemore tube; Type: ACTIVE_COMPARATOR; Interventions: Device: Tamponade | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): Self-expandable esophageal stent | Intervention Type: DEVICE; Name: Tamponade; Assigned to Arm(s): Sengstaken-Blakemore tube
B: Arm Label: Sclerotherapy group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sclerotherapy | Arm Label: Endoscopic band ligation group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Band ligation | Arm Label: Sclero-ligation (SL) group; Type: EXPERIMENTAL; Interventions: Procedure: Scleroligation | Intervention Type: PROCEDURE; Name: Sclerotherapy; Assigned to Arm(s): Sclerotherapy group | Intervention Type: PROCEDURE; Name: Band ligation; Assigned to Arm(s): Endoscopic band ligation group | Intervention Type: PROCEDURE; Name: Scleroligation; Assigned to Arm(s): Sclero-ligation (SL) group
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B
D: Arm Label: EVL plus Somatostatin; Type: EXPERIMENTAL; Interventions: Drug: Somatostatin | Arm Label: EVL plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Somatostatin; Assigned to Arm(s): EVL plus Somatostatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EVL plus Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: San Diego Bleeding Esophageal Varices Study
Brief Summary: In unselected cirrhotic patients with bleeding esophageal varices to compare the influence on mortality rate, duration of life, quality of life, and economic costs of treatment of:

* Emergency portacaval shunt, and
* Emergency and long-term endoscopic sclerotherapy.


Options:
A: Arm Label: Standard therapy + Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: Standard therapy + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Standard therapy + Simvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard therapy + placebo
B: Arm Label: ET+NSBB; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ET+NSBB | Arm Label: TIPS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) | Intervention Type: PROCEDURE; Name: Transjugular intrahepatic portosystemic shunt (TIPS); Assigned to Arm(s): TIPS | Intervention Type: PROCEDURE; Name: ET+NSBB; Assigned to Arm(s): ET+NSBB
C: Arm Label: Ligation and Cyanoacrylate Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ligation and Cyanoacrylate | Arm Label: Ligation plus Sclerotherapy and Cyanoacrylate Group; Type: EXPERIMENTAL; Interventions: Procedure: Ligation plus Sclerotherapy and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation and Cyanoacrylate; Assigned to Arm(s): Ligation and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation plus Sclerotherapy and Cyanoacrylate Group; Assigned to Arm(s): Ligation plus Sclerotherapy and Cyanoacrylate Group
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: San Diego Bleeding Esophageal Varices Study
Brief Summary: In unselected cirrhotic patients with bleeding esophageal varices to compare the influence on mortality rate, duration of life, quality of life, and economic costs of treatment of:

* Emergency portacaval shunt, and
* Emergency and long-term endoscopic sclerotherapy.


Options:
A: Arm Label: Endoscopic Variceal Band Ligation (EVBL); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endoscopic Variceal Band Ligation | Arm Label: Early TIPSS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endoscopic Variceal Band Ligation, Procedure: Transjugular Intrahepatic Porto-Systemic Stent Shunt | Intervention Type: PROCEDURE; Name: Endoscopic Variceal Band Ligation; Assigned to Arm(s): Early TIPSS, Endoscopic Variceal Band Ligation (EVBL) | Intervention Type: PROCEDURE; Name: Transjugular Intrahepatic Porto-Systemic Stent Shunt; Assigned to Arm(s): Early TIPSS
B: Arm Label: ET+NSBB; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ET+NSBB | Arm Label: TIPS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) | Intervention Type: PROCEDURE; Name: Transjugular intrahepatic portosystemic shunt (TIPS); Assigned to Arm(s): TIPS | Intervention Type: PROCEDURE; Name: ET+NSBB; Assigned to Arm(s): ET+NSBB
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B

Answer: D